SCHEMBL480683

SCHEMBL480683

Cn1cc(N)c(=O)n(C)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
ATAD2 Q6PL18 2/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 1/20 0.37
CASP1 P29466 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GLA P06280 1/20 0.36
POLB P06746 3/20 0.35
PIK3CD O00329 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CNR1 P21554 1/20 0.35
ACHE P22303 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30740061 0.98 LMNA (0.38) LMNASMN1; SMN2ATAD2TSHRHTT
SCHEMBL4146947 0.77 CASP6 (0.41) ATAD2KDM4EALDH1A1MAPTPOLB
SCHEMBL21026204 0.77 AURKA (0.33) ATAD2AURKATTKAURKBINCENP
SCHEMBL4621367 0.75
SCHEMBL566202 0.71 GAA (0.43) LMNASMN1; SMN2TSHRHTTKDM4E
SCHEMBL1689852 0.71 LMNA (0.39) LMNASMN1; SMN2TSHRHTTKDM4E
SCHEMBL3189250 0.71 TSHR (0.44) LMNASMN1; SMN2TSHRHTTKDM4E
SCHEMBL3806350 0.71 ERN1 (0.42) LMNASMN1; SMN2TSHRHTTKDM4E
SCHEMBL1527119 0.71 TSHR (0.39) LMNASMN1; SMN2TSHRHTTKDM4E
SCHEMBL24566757 0.71 ALDH1A1 (0.38) LMNASMN1; SMN2ATAD2TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5830867-A Hemoregulatory peptides for stimulating the myelopoietic system SMITHKLINE BEECHAM CORPORATION (US) 1998-11-03 US claimed
EP-0701446-A4 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1997-04-23 EP claimed
EP-0701446-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1996-03-20 EP claimed
WO-1994027627-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-12-08 WO claimed
US-20260022280-A1 LOW VOC SOLVENT CEMENT FORMULATION WITH REDUCED TOXICITY AND RAPID CURING KOKKOT RANJITH (IN) 2026-01-22 US disclosed
CN-119978546-A Solid organic tin composite heat stabilizer technological formula 宁夏睿欣科技发展有限公司 2025-05-13 CN disclosed
WO-2023150592-A2 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D.E. SHAW RESEARCH, LLC (US) 2023-08-10 WO disclosed
US-11708336-B2 Anodic oxidation of 5-aminouracil MEDIBEACON INC. (US) 2023-07-25 US disclosed
CN-109232443-B Pyrimidone derivatives, preparation method and medical application thereof 中国药科大学 2022-03-08 CN disclosed
EP-3272754-B1 IMIDAZOPYRROLIDINONE COMPOUNDS NOVARTIS AG (CH) 2019-05-29 EP disclosed
EP-3272754-B1 IMIDAZOPYRROLIDINONE COMPOUNDS NOVARTIS AG (CH) 2019-05-29 EP disclosed
CN-109232443-A Pyrimidone derivatives, preparation method and medical usage 中国药科大学 2019-01-18 CN disclosed
CN-1492870-A Xanthine derivatives, process for their preparation and their use as pharmaceutical compositions ���ָ��Ӣ��ķ�������Ϲ�˾ 2004-04-28 CN disclosed
EP-1406962-A1 USE OF AMINOURACILS FOR STABILISING ANTISTATIC ORGANIC PLASTICS CONTAINING HALOGEN Cognis Deutschland GmbH & Co. KG (DE) 2004-04-14 EP disclosed
WO-2003056061-A2 POLYMER DERIVATIVES FOR THE TREATMENT OF METALS BASF AKTIENGESELLSCHAFT (DE) 2003-07-10 WO disclosed
WO-2003004556-A1 USE OF AMINOURACILS FOR STABILISING ANTISTATIC ORGANIC PLASTICS CONTAINING HALOGEN COGNIS DEUTSCHLAND GMBH & CO. KG (DE) 2003-01-16 WO disclosed
US-5830867-A Hemoregulatory peptides for stimulating the myelopoietic system SMITHKLINE BEECHAM CORPORATION (US) 1998-11-03 US disclosed
EP-0701446-A4 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1997-04-23 EP disclosed
EP-0701446-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1996-03-20 EP disclosed
WO-1994027627-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708336-B2 Anodic oxidation of 5-aminouracil DPYD, DHODH, AASDHPPT LMNA 3508/4885SMN1; SMN2 2424/4885ATAD2 960/4885
US-20260022280-A1 LOW VOC SOLVENT CEMENT FORMULATION WITH REDUCED TOXICITY AND RAPID CURING JMJD1C, KDM5C, SUV39H2 LMNA 3002/4885SMN1; SMN2 2573/4885ATAD2 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.